CEO, Chief Executive Officer
Chris joined Cell Medica from the cancer immunotherapy company Kite Pharma (Kite), where he was Head of Europe and responsible for the full commercialisation of the CAR-T therapy axicabtagene ciloleucel. At Kite he built the European organisation from the ground up and, post the $12 Bn acquisition by Gilead Sciences in 2017, was subsequently responsible for the continued expansion of the Kite organisation within the Europe, Middle East and Africa structure. Previous to his role at Kite, he has had a career spanning more than 25 years in the biopharma industry. He has held a number of senior leadership roles that included CEO of Avantogen Oncology, General Management roles at Amgen, and senior global and regional commercial leadership roles at Bristol-Myers Squibb (BMS). Whilst at BMS, he built and led teams that delivered the successful launches of the checkpoint inhibitors ipilimumab and nivolumab.
Dr Annalisa Jenkins
Chair of the Board of Directors
Annalisa Jenkins, MBBS, FRCP, joined the Board of Directors as Chairperson in December 2017. Prior to joining Cell Medica, Dr. Jenkins served as President and CEO of Dimension Therapeutics and held multiple leadership positions, including Executive Vice President, Head of Global Research and Development for Merck Serono, where she led global medical affairs and quality and was a member the Pharmaceutical Executive Committee. Prior to this, Dr. Jenkins had a successful 14-year career at Bristol-Myers Squibb (BMS), attaining the role of Senior Vice President and Head of Global Medical Affairs. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital, University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service. Dr. Jenkins is a board member of several growing companies and a member of the Science Board to the U.S. Food & Drug Administration (FDA). She also serves on the board of the Center for Talent Innovation in the U.K.
Dr Thomas Hecht
Thomas has been on the Cell Medica Board since 2012 and he was Chairman until December 2017. He was previously Vice President Marketing at Amgen Europe, Lucerne, Switzerland. Following his academic career, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
Today, he provides services to the pharmaceutical industry in clinical development/ marketing and licensing strategies.
He also serves as Chairman of Affimed NV, Vaximm AG and Aelix Therapeutics SA. In 2009, with the acquisition by Alcon, he stepped down as Chairman of ESBATech AG; and in 2015, with the acquisition by Baxter International Inc., from his post as Chairman of the Supervisory Council of SuppreMol GmbH.
Thomas earned his MD at the University of Freiburg.
Julia P. Gregory
Non-Executive Director and Audit Chair
Julia P. Gregory, Chairman and CEO of Isometry Advisors, Inc., a biotechnology financial and management advisory firm, has 16 years of executive management experience and 20 years of investment banking experience. As an executive, she successfully raised more than $1.5 billion for her companies through initial public offerings, public and private offerings and creative strategic alliances including GlaxoSmithKline, BristolMyers Squibb, Takeda Pharmaceuticals, Genentech, (Roche) and Human Genome Sciences (GSK), among others. She was formerly CEO of the novel antibiotics company, ContraFect Corporation, CEO of FivePrime Therapeutics, an immuno-oncology company, and EVP, Head of Corporate Development and CFO of Lexicon Pharmaceuticals where she lead the Company’s $220 million IPO. She is currently on the board of directors of Iconic Therapeutics, IMV Corporation, the Sosei Group and Biohaven Therapeutics. Ms. Gregory attained a Masters of Business Administration from the Wharton School at the University of Pennsylvania, and earned her B.A. at the George Washington University.
Dr Nigel Burns
Nigel has extensive experience in product and company management and has held a series of leadership roles, one of which was Senior Vice President at Cambridge Antibody Technology. Nigel has also held a number of Board level positions in companies such as Glythera and currently at Cell Medica. Additionally, he was formerly non-executive Director of Navion, Director and Founder of Nascient and, most recently, CEO and Founder of SweetSpot Therapeutics Ltd. Furthermore, he was an entrepreneur-in-residence for Imperial Innovations and has served on multiple national and international scientific and industry advisory boards and committees.
Nigel has a PhD in biophysics from King’s College, London and a BSc in biochemistry from Imperial College London.
Dr Allan Marchington
Allan Marchington is an experienced investor with a strong track record of success. In 2006 Allan and his Partners founded Apposite Capital, an international healthcare investment company based in London. While at Apposite, Allan has served on the Board of a number of companies including Calchan Ltd., Birdrock Bio Inc., Ambrx Inc., Ambit Biosciences Inc., Convergence Pharmaceuticals Ltd, and Sotera Wireless. Prior to establishing Apposite, Allan worked in a number of senior roles, including Entrepreneur in Residence, Abingworth Management and Senior Vice President, Millennium Pharmaceuticals Inc. based in Cambridge Mass. Prior to Millennium, Allan was principal founder and CEO of Cambridge Combinatorial, a combinatorial chemistry company which was successfully sold to Millennium in 2000. Allan has a PhD in Chemistry from the University of Liverpool and after leaving University, worked for seven years in a range of therapeutic areas at Pfizer.
Sam is Managing Partner, Life Sciences, at IP Group plc. He has 20 years’ experience in the biotech sector, both as a top-ranked equity analyst in the City of London and, subsequently, as a chief executive. He currently serves as Executive Chairman of Istesso Ltd, Chairman of Glythera Ltd and a non-executive director of Diurnal Group plc, C4X Discovery Holdings plc and Microbiotica Ltd. Sam has a PhD in molecular biology from Cambridge and a degree in biology from Oxford.